Device
18F-FDG PET Scan
18F-FDG PET Scan is a medical device with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
3
60%
Ph phase_1
2
40%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
N/ANon-phased studies
3(60.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (40.0%)
N/A3 (60.0%)
Trials by Status
completed240%
recruiting120%
unknown240%
Recent Activity
1 active trials
Showing 5 of 5
completednot_applicable
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
NCT01916057
recruitingphase_1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
NCT01542879
unknownnot_applicable
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
NCT03121456
completedphase_1
Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS
NCT02124941
unknownnot_applicable
Neuromolecular Risk Factors for Obesity (PROSPECT)
NCT03106688
Clinical Trials (5)
Showing 5 of 5 trials
NCT01916057Not Applicable
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
NCT01542879Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
NCT03121456Not Applicable
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
NCT02124941Phase 1
Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS
NCT03106688Not Applicable
Neuromolecular Risk Factors for Obesity (PROSPECT)
All 5 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 5